APOPTOSIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Apoptosis Market, By Application (Oncology, Neurodegenerative Diseases, Autoimmune Disorders, Cardiovascular Diseases, and Others), By Modality (Apoptosis Assays, Apoptosis Antibodies, and Apoptosis Inhibitors and Inducers), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations, and Ohers), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In December 2022, TransGen has launched a series of Annexin V detection kits for early apoptosis detection. These kits are highly sensitive, specific, and easy to use, suitable for flow cytometry and fluorescence microscopy. The TransDetect Annexin V-FITC/PI Cell Apoptosis Detection Kit is highlighted for its ability to differentiate between live, apoptotic, and necrotic cells using FITC and Propidium Iodide (PI) staining.
In September 2022, Merck announced that its Inhibitor of Apoptosis Protein (IAP), xevinapant (formerly known as Debio 1143), combined with chemoradiotherapy (CRT), had significantly enhanced long-term efficacy outcomes for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) compared to placebo combined with CRT.